Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients

Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients - Comparison of CCB and thiazide diuretics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005064

Enrollment

Registered

2011-02-11

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetic patients with hypertension

Interventions

azelnidipine (16 mg/day) trichlormethiazide (1 mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were patients with type 2 diabetes mellitus and hypertension in whom the target clinic blood pressure (<130/80 mmHg) could not be achieved despite treatment with olmesartan 20 mg once daily

Exclusion criteria

Exclusion criteria: Patients with HbA1c higher than 8.4% were excluded from the study. In addition, patients with severe renal or hepatic disease, overt cardiovascular disease, and malignancy were excluded

Design outcomes

Primary

Measure	Time frame
Comparison of the effects on blood pressure (BP) and various metabolic parameters.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026